Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cannabis
- Delivery
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305318
The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.
Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.
Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.
The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.
Licensor’s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.
With concern growing over vaping and the numerous incidents now being reported, Licensee’s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles. Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.
IPSCIO Record ID: 241951
Licensed Product shall mean Licensor’s patch described below hereto in combination with Cannabidiol (CBD) for medical or recreational cannabis, where latter permitted for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted (other than in the field of oral care) or any other product exploiting the Licensee Cannabis IP for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted.
Description of Patch – A “Eluting Transmucosal Patch Platform (ETP)†for non-invasive drug delivery.
Licensor Patents shall mean those patents and patent applications listed below, as well as patents issuing therefrom, and any substitutions, divisions, continuations, continuations-in-part (but only to the extent that they cover the same invention claimed in the foregoing), reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any such patents or patent applications.
Patent(s)/Patent Application(s)
1. WO 2012/104834 A1
New oral dissolving films for insulin administration, for treating diabetes.
filed on December 2011. National Phase at Israel and the USA.
2. WO 2010/135053 A2
Dual and single layer dosage forms.
Issued USA patent on April 28, 2015.
3. PCT/IL 2017/050845
Adhesive Oral dissolved Films in Managing Oral Care.
PCT on 31 July 2017.
IPSCIO Record ID: 269589
IPSCIO Record ID: 204556
Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.
BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.
The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.
IPSCIO Record ID: 27852
Licensor's most advanced product in development using RapidMistâ„¢ is Generex Oral-lynâ„¢, an insulin spray product for the treatment of diabetes mellitus.
